Celldex Therapeutics Inc (TCE2 STU) stock market data APIs
€17.1607
0(0%)
as of April 25, 2025
Celldex Therapeutics Inc Financial Data Overview
Prev. Close
17.1607
Open
17.1607
High
16.988
Low
17.1607
52 wk Range
13.3-40.8
Market Cap
1 512 M
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Celldex Therapeutics Inc data using free add-ons & libraries
Get Celldex Therapeutics Inc Fundamental Data
Celldex Therapeutics Inc Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Celldex Therapeutics Inc News
New
Cytokinetics (CYTK) Moves 5.4% Higher: Will This Strength Last?
Cytokinetics (CYTK) shares rallied 5.4% in the last trading session to close at $45.43. This move can be attributable to notable volume with a higher number of shares being traded than in a typical se...
Celldex Therapeutics to Present at Upcoming Investor Conferences
Celldex Therapeutics, Inc. HAMPTON, N.J., March 04, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in fireside chats at two upcomin...
Celldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025
Celldex Therapeutics, Inc. - CDX-622 inhibits SCF and TSLP-dependent inflammatory signatures in human skin - - Phase 1 study in healthy volunteers ongoing - HAMPTON, N.J., March 03, 2025 (GLOBE NEWS...
Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025
Celldex Therapeutics, Inc. - Greatly improved patient quality of life and reduced disease impact in patients with CSU and CIndU - - 82% of CSU patients reported that symptoms no longer had an impact ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
